低剂量氯胺酮作为吗啡辅助用药:一项在有或无当前阿片类药物使用的患者中进行的随机对照试验
该随机对照试验纳入116例急诊急性疼痛(数字评分≥5分)且需静脉阿片类药物的成人患者,分别在有或无当前阿片类药物使用的人群中随机接受0.1 mg/kg氯胺酮或生理盐水辅助吗啡。主要终点T0至T10疼痛缓解在氯胺酮组为4(IQR 3-6),安慰剂组为1(IQR 0-2),p=0.001。氯胺酮组在T10、T20、T30疼痛强度更低。氯胺酮组前10分钟恶心、呕吐和分离感风险更高。作者认为低剂量氯胺酮可能作为吗啡辅助镇痛用于急诊急性疼痛的短期缓解,无论患者有无当前阿片类药物使用。
要点
- 急诊急性疼痛(数字评分≥5分)需静脉阿片类药物者,0.1 mg/kg氯胺酮辅助吗啡较安慰剂T0至T10疼痛缓解更大(4 vs 1,p=0.001)。
- 氯胺酮组在T10、T20、T30疼痛强度低于安慰剂组。
- 氯胺酮组前10分钟恶心、呕吐和分离感风险更高。
- 作者认为低剂量氯胺酮可能作为吗啡辅助镇痛用于急诊急性疼痛的短期缓解,无论患者有无当前阿片类药物使用。
适用人群与场景
- 急诊科成人患者,急性疼痛数字评分(0-10)≥5分,且经治急诊医师认为需要静脉阿片类药物。
- 有或无当前阿片类药物使用的患者分别随机。
诊断标准与关键阈值
- 急性疼痛数字评分(0-10)≥5分。
处置流程与药物剂量
- 低剂量氯胺酮组:0.1 mg/kg 氯胺酮作为吗啡辅助用药。
- 安慰剂组:生理盐水作为吗啡辅助用药。
- 疼痛在基线(T0)及随机后10、20、30、45、60、120分钟测量。
研究设计与关键结果
- 随机对照试验,纳入116例患者,时间2022年5月至2023年8月;中位(IQR)年龄51(36.5-67)岁,58%男性,36%有当前阿片类药物使用。
- 主要终点T0至T10疼痛缓解:低剂量氯胺酮组4(IQR 3-6)vs 安慰剂组1(IQR 0-2),p=0.001。
- 次要终点:低剂量氯胺酮组在T10、T20、T30疼痛强度低于安慰剂组;前10分钟恶心、呕吐和分离感风险更高。
证据类型、等级与局限
- 证据类型:随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为低剂量氯胺酮可能作为吗啡辅助镇痛用于急诊急性疼痛的短期缓解,无论患者有无当前阿片类药物使用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Pain is a common complaint among patients presenting to the emergency department (ED), yet pain treatment is frequently suboptimal. The aim of this study was to determine the effectiveness of low-dose ketamine (LDK) as an adjunct to morphine versus morphine alone for treatment of acute pain among ED patients with and without current opioid use.
METHODS: Adult patients presenting with acute pain of ≥5 on a numeric rating scale (0-10) who were deemed by their treating ED physician to require intravenous opioids were randomized to receive either 0.1 mg/kg ketamine (treatment group) or isotonic saline (placebo) as an adjunct to morphine. Patients with and without current opioid use were randomized separately. Pain was measured at baseline (T0) and 10, 20, 30, 45, 60, and 120 min after randomization. The primary outcome was pain reduction from T0 to T10. Secondary outcomes included pain intensity over 120 min, need of rescue opioids, side effects, and patient and provider satisfaction.
RESULTS: A total of 116 patients were included from May 2022 to August 2023. Median (IQR) age was 51 (36.5-67) years; 58% were male and 36% had current opioid use. Pain reduction from T0 to T10 was greater in the LDK group (4 [IQR 3-6]) compared to the placebo group (1 [IQR 0-2]; p = 0.001). Pain intensity was lower in the LDK group at T10, T20, and T30, compared to the placebo group. There was a higher risk of nausea, vomiting, and dissociation in the LDK group during the first 10 min.
CONCLUSIONS: LDK may be effective as an adjunct analgesic to morphine for short-term pain relief in treatment of acute pain in the ED for both patients with and without current opioid use.
参考来源
- Galili SF, Bech BH, Kirkegaard H, et al. Low-dose ketamine as an adjunct to morphine: A randomized controlled trial among patients with and without current opioid use. Acad Emerg Med. 2024. PMID: 39014886. doi:10.1111/acem.14983
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。